Korea's Celltrion Develops Universal "Super Flu-Antibody Therapy"
This article was originally published in PharmAsia News
Executive SummarySEOUL - South Korean biopharma company Celltrion has developed a human monoclonal antibody product that could be effective against multiple influenza viruses such as the pandemic H1N1 and the H5N1 avian influenza virus
You may also be interested in...
Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).